The Dupixent® (dupilumab) trial in the treatment of eosinophilic esophagitis meets the two co-main evaluation criteria

Forward-looking statements – Sanofi

This press release contains forward-looking statements. These statements are not historical facts. These statements include projections and estimates and the assumptions on which they are based, statements regarding projects, objectives, intentions and expectations regarding financial results, events, operations, future services, the product development and their potential or future performance. These forward-looking statements can often be identified by the words “expect”, “anticipate”, “believe”, “intend to”, “estimate” or “plan”, as well as other similar terms. Although the management of Sanofi believes that these forward-looking statements are reasonable, investors are alerted to the fact that these forward-looking statements are subject to numerous risks and uncertainties, which are difficult to predict and generally outside of Sanofi’s control, which may imply that actual results and events achieved differ significantly from those expressed, implied or expected in the information and forward-looking statements. These risks and uncertainties include in particular the uncertainties inherent in research and development, future clinical data and analyzes, including post-market, decisions of regulatory authorities, such as the FDA or EMA, approval or not, and on what date, of the request for the filing of a drug, process or biological product for one of these candidate products, as well as their decisions relating to labeling and others factors that may affect the availability or commercial potential of these product candidates, the fact that product candidates if approved may not be commercially successful, future approval and commercial success of therapeutic alternatives, the ability to Sanofi to seize external growth opportunities and finalize related transactions, changes in exchange rates and interest rates, instability of co economic and market editions, cost control initiatives and their evolution, the impact that COVID-19 will have on Sanofi, its customers, suppliers and partners and their financial situation, as well as on its employees and on the economy world. Any significant impact on the latter could negatively impact Sanofi. The situation is evolving rapidly and other consequences that we ignore may appear and exacerbate the risks previously identified. These risks and uncertainties also include those developed or identified in the public documents filed by Sanofi with the AMF and the SEC, including those listed in the “Risk Factors” and “Forward-Looking Statements” sections of the Document Sanofi 2019 universal registration, which has been filed with the AMF as well as in the “Risk Factors” and “Cautionary Statement Concerning Forward-Looking Statements” sections of the 2019 annual report on Sanofi Form 20-F, which has been filed to the SEC. Sanofi makes no commitment to update forward-looking information and statements subject to applicable regulations, in particular articles 223-1 et seq. Of the general regulations of the Autorité des Marchés Financiers.

Forward-looking statements and the use of digital media – Regeneron

This press release contains forward-looking statements regarding risks and uncertainties related to future events and the future performance of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”). Actual events or results may differ materially from this forward-looking information. Terms such as “anticipate”, “expect”, “intend”, “plan”, “believe”, “research”, “estimate”, variations of these terms and similar expressions are intended identify these forward-looking statements, although not all forward-looking statements contain these explicit terms. These statements relate to, and these risks and uncertainties include, among other things, the impact that SARS-CoV-2 (the virus causing the COVID-19 pandemic) can have on activities, employees, collaborators and Regeneron’s suppliers, as well as other third parties on which the company relies, on the ability of Regeneron and its collaborators to continue to conduct research and clinical programs (including those discussed herein press release), on Regeneron’s ability to manage its supply chain, the net sales of products marketed by Regeneron and / or its employees (hereinafter, “Regeneron products”), and on the economy worldwide; the nature, timing, as well as the success and possible therapeutic applications of Regeneron products and product candidates and current or planned research and clinical programs, including, without limitation, those devoted to Dupixent® (dupilumab) at children aged 6 to 11 years with moderate to severe atopic dermatitis; the uncertainty of market acceptance and commercial success of Regeneron products and product candidates and the impact of studies (whether conducted by Regeneron or others and whether they are mandated or voluntary) on success sales of such products and product candidates; the likelihood, timing and extent of possible regulatory approval and commercial launch of product candidates and new indications for Regeneron products, such as dupilumab for the treatment of pediatric asthma, pediatric atopic dermatitis , eosinophilic esophagitis, chronic obstructive pulmonary disease, bullous pemphigoid, nodular prurigo, chronic spontaneous urticaria, food and environmental allergies and for other potential indications (as well as in combination with REGN3500); unexpected safety concerns resulting from the administration of Regeneron product and product candidates (such as Dupixent) to patients, including serious complications or adverse reactions related to the use of Regeneron product and product candidates clinical trials; decisions of regulatory and administrative authorities liable to delay or limit the ability of Regeneron to continue to develop or market its products and product candidates; regulatory requirements and ongoing monitoring affecting Regeneron products, research and clinical programs and business activities, including those relating to patient privacy; the availability and extent of reimbursement of Regeneron products (such as Dupixent) by third-party payers, HMOs, healthcare management organizations and public plans such as Medicare and Medicaid; the decisions regarding the assumption and reimbursement by these third-party payers and the new policies and procedures that they may adopt; the possibility that competing drugs or drug candidates are superior to Regeneron’s products and product candidates; the extent to which the results of research and development programs conducted by Regeneron or its collaborators can lead to clinical trials and therapeutic applications; Regeneron’s ability to manufacture and manage supply chains for multiple products and product candidates; the ability of Regeneron’s collaborators, suppliers or other third parties (if applicable) to perform manufacturing, filling, finishing, packaging, labeling, distribution and other steps related to products and products- Regeneron candidates; unforeseen expenses; costs of product development, production and sales; Regeneron’s ability to meet its forecasts or financial forecasts and to modify the underlying assumptions; the possibility that any license or collaboration agreement, including Regeneron’s agreements with Sanofi, Bayer and Teva Pharmaceutical Industries Ltd. (or their respective affiliates, if any), be canceled or terminated without further product success; and risks related to the intellectual property of other parties and to current or future litigation, including, without limitation, patent litigation and other related procedures relating to Dupixent® and Praluent® (alirocumab), any other litigation and any other procedure and government inquiry into the company and / or its activities, the outcome of any such procedure and the impact that the above may have on the activities, prospects , results of operations and financial condition of Regeneron. A more complete description of these risks, as well as other significant risks, is contained in documents filed by Regeneron with the United States Securities and Exchange Commission, in particular in its Form 10-K for the year ended 31 December 2019 and in its Form 10-Q for the quarter ended March 31, 2020. All forward-looking statements are based on current beliefs and judgment of management and readers are cautioned not to rely on the forward-looking statements made by Regeneron . Regeneron assumes no obligation to publicly update forward-looking statements, including, but not limited to, projections or financial forecasts, whether as a result of new information, future events or otherwise.

Regeneron uses its dedicated investor relations and media relations website and social media to post important information about the Company, including information that may be considered important to investors. Financial and other information about Regeneron is regularly published and accessible on its website dedicated to investor relations and media relations (http://newsroom.regeneron.com) and on its Twitter feed (http: // twitter .com / regeneron).